14 May, 2017
Canaccord Genuity restated their buy rating on shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) in a report released on Friday, April 28th.
Several other analysts also recently issued reports on the company. Canaccord Genuity set a $144.00 price objective on Zimmer Biomet Holdings and gave the stock a "buy" rating in a report on Tuesday, January 31st. Finally, Zacks Investment Research cut Zimmer Biomet Holdings from a "hold" rating to a "sell" rating in a report on Tuesday, April 4th.
11/01/2016 - Zimmer Biomet Holdings, Inc. had its " rating reiterated by analysts at RBC Capital. Zimmer Biomet Holdings had 30 analyst reports since August 27, 2015 according to SRatingsIntel. Breaking those down we see that the ratings are as follows: 11 Strong Buy, 2 Rated Buy, 7 Rated Hold and 0 Rated Sell. The median target of analyst views collected by Yahoo Finance was as much as $12.98 below ZBH's recent stock price.
Shares of Zimmer Biomet Holdings (NYSE:ZBH) traded up 0.68% during midday trading on Thursday, hitting $120.30. Finally, Morgan Stanley boosted its stake in shares of Zimmer Biomet Holdings by 41.6% in the third quarter.
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The medical equipment provider reported $2.13 EPS for the quarter, beating analysts' consensus estimates of $2.11 by $0.02.
Contango Oil & Gas Company (:MCF) shares have moved -1.63% on the week. The business had revenue of $1.98 billion during the quarter, compared to analyst estimates of $1.96 billion. Year to date Contango Oil & Gas Company (:MCF) is -22.59%, -14.64% over the last quarter, and -14.74% for the past six months. John G Ullman & Associates Inc.'s holdings in Zimmer Biomet Holdings were worth $1,479,000 at the end of the most recent quarter. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and worldwide trademark and copyright laws. If you are accessing this report on another website, it was copied illegally and republished in violation of US and global copyright and trademark law. Stockholders of record on Friday, March 31st were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. Zimmer Biomet Holdings's payout ratio is now 65.31%. The 52-week range of the share price is from $95.63 - $133.21, while its earnings per share (EPS) was $2.44. The company has a 50 day moving average price of $120.43 and a 200-day moving average price of $113.14. Huntington National Bank now owns 10,033 shares of the medical equipment provider's stock worth $1,305,000 after buying an additional 1,905 shares during the period. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
EPS is the portion of a company's profit allocated to each exceptional share of common stock. This is the signal from the 100-day MA which is used to gauge changes in stock price. The disclosure for this sale can be found here. The shares have slowed down in recent weeks, with their price down about -0.08% in the past three months.
A number of hedge funds have recently modified their holdings of the stock. Acrospire Investment Management LLC purchased a new stake in shares of Zimmer Biomet Holdings during the third quarter worth $130,000. Conning Inc. now owns 4,656 shares of the medical equipment provider's stock worth $605,000 after buying an additional 380 shares in the last quarter.
06/08/2016 - Guggenheim began new coverage on Zimmer Biomet Holdings, Inc. giving the company a "neutral" rating. Boston Advisors LLC now owns 17,212 shares of the medical equipment provider's stock worth $2,238,000 after buying an additional 15,005 shares in the last quarter. Volume on the day was 1.35 million shares.
11/08/2016 - Zimmer Biomet Holdings, Inc. was downgraded to " by analysts at Northcoast Research.
